Bms911543

Manufactured by Chemietek

The BMS911543 is a laboratory equipment designed for general laboratory applications. It is a versatile instrument that can be utilized for various scientific experiments and analyses. The core function of this product is to perform precise measurements and data collection tasks within a controlled laboratory environment.

Automatically generated - may contain errors

Lab products found in correlation

Ruxolitinib, by Chemietek (1 mentions) Chz868, by Novartis (1 mentions) Cyt387, by Chemietek (1 mentions) Tg101348, by Selleck Chemicals (1 mentions) Azd1480, by Selleck Chemicals (1 mentions) Collagenase type 1, by Thermo Fisher Scientific (1 mentions) 4 hydroxytamoxifen 4 oht, by Merck Group (1 mentions) Egfr sc 03, by Santa Cruz Biotechnology (1 mentions) Cleaved caspase 3, by Cell Signaling Technology (1 mentions) Erk1 2, by Cell Signaling Technology (1 mentions) 17β estradiol e2, by Merck Group (1 mentions) Monoclonal anti clcf1 antibody, by R&D Systems (1 mentions)

4 protocols using bms911543

Oral Administration of Novel JAK Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

CHZ868 was synthesized by Novartis and stored at 1mM in DMSO for in vitro use. For in vivo applications, CHZ868 was administered orally at 15 mg/kg twice daily (bid) or at 15, 20, 30 or 40 mg/kg once daily (qd). CYT387, BMS911543 and ruxolitinib were purchased from Chemietek. SAR302503 was synthesized as described(Marubayashi et al., 2010 (link)); these agents were stored at 1mM in DMSO at −20°C.

Meyer S.C., Keller M.D., Chiu S., Koppikar P., Guryanova O.A., Rapaport F., Xu K., Manova K., Pankov D., O’Reilly R.J., Kleppe M., McKenney A.S., Shih A.H., Shank K., Ahn J., Papalexi E., Spitzer B., Socci N., Viale A., Mandon E., Ebel N., Andraos R., Rubert J., Dammassa E., Romanet V., Dölemeyer A., Zender M., Heinlein M., Rampal R., Weinberg R.S., Hoffman R., Sellers W.R., Hofmann F., Murakami M., Baffert F., Gaul C., Radimerski T, & Levine R.L. (2015). CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer cell, 28(1), 15-28.

+ Open protocol

+ Expand

Sialidase-Modulated Platelet-Induced STAT3 Phosphorylation

Check if the same lab product or an alternative is used in the 5 most similar protocols

HepG2 cells (purchased from ATCC-HB-8065) were grown at 4×10⁵ cells/cm² in Permanox® (Nalge Nunc International) slides for 24 h in the presence of 2 μM AZD1480 or 10 μM of TG101348 (both Selleckchem) or 2 μM of BMS911543 (Chemie Tek) or vehicle before addition of human platelets treated or non-treated with sialidase. Immunofluorescence for anti-pSTAT3 (Cell Signaling Technology) was performed 1 h after platelet addition to HepG2 cells following antibody manufactor’s protocol. After 6 h incubation with humans platelets treated or non-treated with sialidase, HepG2 cells were fixed in 4% PFA, followed by permeabilization in 2% Triton X-100. Cells were incubated for 30 min at 37 °C with 5% goat-serum to block unspecific binding and incubated overnight at 4 °C with a polyclonal anti-human TPO antibody (R&D Systems, USA) followed by secondary AlexaFluo®568 conjugated polyclonal goat-anti rabbit antibody (Invitrogen). Nuclei were visualized by inclusion of 4′, 6-diamino-2-phenyllidole (DAPI) (Invitrogen) in the mounting medium.

Grozovsky R., Begonja A.J., Liu K., Visner G., Hartwig J.H., Falet H, & Hoffmeister K.M. (2014). The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nature medicine, 21(1), 47-54.

+ Open protocol

+ Expand

Estrogen Receptor Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

17β-estradiol (E2) was purchased from Sigma-Aldrich (St. Louis, MO). Recombinant hPRL (Lot AFP795) was obtained from Dr. A.F. Parlow (National Hormone and Pituitary Program, NIDDK, National Institutes of Health, Torrance, CA). Type-I rat tail collagen (#CB354249) was obtained from Fisher Scientific (Pittsburgh, PA). Inhibitors used for these studies were purchased as follows: 4-hydroxy-tamoxifen (4-OHT) (#579002) from EMD Millipore (Billerica, MA), SFK inhibitor, PP-1 (#EI275) from Biomol International, LP (Plymouth Meeting, PA), and JAK2 inhibitor, BMS-911543 (#CT-BMS91) from Chemietek (Indianapolis, IN). Type-I collagenase (#17100–017) was purchased from Invitrogen (Grand Island, NY). Antibodies used in these studies were as follows: PRLR-ECD (#35–9200) and pSRC Y418 (#44660G) from Invitrogen (Grand Island, NY); ERK1/2 (#9102) and cleaved caspase-3 (#9661) from Cell Signaling Technology (Danvers, MA); cSRC (sc-18) and EGFR (sc-03) from Santa Cruz Biotechnology (Santa Cruz, CA); ERα (#NCL-ER-6F211/2) from Novocastra (Newcastle, United Kingdom); pan-actin (#125-ACT) from Phosphosolutions (Aurora, CO); Ki-67 (#AB15580) from Abcam (Cambridge, MA). Multiwell non-tissue culture-treated plates were obtained from Corning Life Sciences (#08–772–49 and #08–772–51, Tewksbury, MA). All other reagents were obtained from Fisher Scientific or Sigma-Aldrich.

Barcus C.E., Holt E.C., Keely P.J., Eliceiri K.W, & Schuler L.A. (2015). Dense Collagen-I Matrices Enhance Pro-Tumorigenic Estrogen-Prolactin Crosstalk in MCF-7 and T47D Breast Cancer Cells. PLoS ONE, 10(1), e0116891.

+ Open protocol

+ Expand

Recombinant CLCF-1 and Anti-CLCF-1 Antibody

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human CLCF-1 (rhCLCF-1) and monoclonal anti-CLCF-1 antibody were obtained from R&D Systems, Minneapolis, MN. Buffers and media were prepared using chemicals obtained from Sigma-Aldrich (St. Louis, MO). These reagents were stored following the vendors' guidelines. Working solutions were prepared in medium containing 5% BSA. The JAK2 inhibitor BMS-911543 was obtained from ChemieTek, Indianapolis, IN. Stock solutions were prepared and stored following instructions of suppliers/manufacturers.

Savin V.J., Sharma M., Zhou J., Gennochi D., Fields T., Sharma R., McCarthy E.T., Srivastava T., Domen J., Tormo A, & Gauchat J.F. (2015). Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. Journal of Immunology Research, 2015, 714964.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!